Rybrevant Receives Accelerated Approval to Treat Lung Cancer
May 21, 2021Myfembree Approved to Manage Heavy Menstrual Bleeding Due to Uterine Fibroids
May 26, 2021Camcevi Approved to Treat Prostate Cancer
May 26, 2021 – The U.S. FDA has approved Camcevi® (leuprolide mesylate), manufactured by Foresee Pharmaceuticals, to treat advanced prostate cancer in adults.
Prostate cancer is one of the most common cancers in males, and though it is highly treatable in early stages, survival rates drop significantly in advanced stages of the disease. One treatment avenue includes chemical castration, in which drugs are used to reduce the body’s production of testosterone. This can help reduce the proliferation of prostate cancer cells.
In a clinical study, 97% of patients on Camcevi achieved a mean testosterone concentration suppressed below castrate levels to 17.6ng/dL on day 28. The active pharmaceutical ingredient (API) of Camcevi, leuprolide mesylate, is already FDA approved as an API in multiple treatments for prostate cancer, though the dosing frequency and route of administration vary between products. The recommended dosing for Camcevi is one 42mg subcutaneous injection administered by a healthcare provider every six months.
Launch and pricing information are not yet available.